Friday, July 10, 2026

pharma · Aplastic Anemia · Advanced Hepatocellular Carcinoma

Kyowa Kirin International

Kyowa Kirin International clinical programs — 6 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

GB HQ
1995 Founded
690 Employees
TGA registrant Type
Company details
Status
Public
HQ
GB
Founded
1995
Employees
690
Programs
15
Drugs
12
Patents
0
Intelligence · Clinical Programs

Kyowa Kirin International projects

6 ClinicalTrials.gov programs sponsored by Kyowa Kirin International.

Kyowa Kirin International has 6 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. AMG531

    KYOWA KIRIN AUSTRALIA PTY LTD

    Aplastic Anemia

    phase 2 small molecule completed

    1 trial
  2. Entinostat

    KYOWA KIRIN AUSTRALIA PTY LTD

    Advanced or Recurrent Breast Cancer

    phase 2 small molecule completed

    1 trial
  3. KHK7580

    KYOWA KIRIN AUSTRALIA PTY LTD

    Hyperparathyroidism

    phase 2 small molecule completed

    1 trial
  4. KW-2478

    KYOWA KIRIN AUSTRALIA PTY LTD

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial
  5. POTELIGEO 4 mg/mL concentrate for solution for infusion

    KYOWA KIRIN AUSTRALIA PTY LTD

    Mycosis fungoides/Sezary syndrome recurrent

    phase 2 small molecule active

    1 trial
  6. saxagliptin

    KYOWA KIRIN AUSTRALIA PTY LTD

    Diabetes, Type 2

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Kyowa Kirin International have?

6 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.